Chronic Myeloid Leukemia – Epidemiology – Europe Data
Clarivate Epidemiology’s coverage of chronic myeloid leukemia (CML) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of CML for each country, as well as annualized case counts projected to the national population.
Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets of the United States, Europe, and Japan and 10 years for the other countries covered in this report. In addition to forecasting incident and prevalent patient populations, we estimate the number of drug-treatment opportunities in specific lines of therapy in the developed world.
Clarivate Epidemiology’s CML forecast will answer the following questions:
- In developing countries, what impact will economic growth and development have on the number of people diagnosed with CML per year?
- How will improvements in survival change the number of people diagnosed with CML per year?
- Of all people diagnosed with CML, how many in each country are drug-treated?
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of CML over the forecast period?
All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods. In addition, we provide a graph depicting the patient flow between or within different disease states. These patient-flow diagrams are provided at the regional level but may be requested for any specific country or forecast year.
Clarivate Epidemiology provides at least 10 years of forecast data for the following CML patient populations:
- Diagnosed incident cases of CML.
- Diagnosed incident cases of CML by phase distribution.
- Diagnosed prevalent cases of CML.
Table of contents
- Chronic Myeloid Leukemia - Epidemiology - Europe Data
- Introduction
- Incidence of Chronic Myeloid Leukemia per Year per 100,000 People of All Ages in 2021 and 2031ttttttttt
- Relative Sizes of the Factors Contributing to the Trend in Incident Cases of Chronic Myeloid Leukemia Over the Next 10 Yearstttttttt
- Incidence of Chronic Myeloid Leukemia per Year per 100,000 People of All Ages in 2021 and 2031ttttttttt
- Prevalence of Chronic Myeloid Leukemia per Year per 100,000 People of All Ages in 2021 and 2031ttttt
- Relative Sizes of the Factors Contributing to the Trend in Prevalent Cases of Chronic Myeloid Leukemia Over the Next 10 Yearstttttttt
- Epidemiology Data
- Methods
- Diagnosed Incident Cases
- Phase at Diagnosis
- Diagnosed Prevalence
- Drug-Treated Prevalence
- Progression Events
- Reference Materials
- Literature Review
- Studies Included in the Analysis of Chronic Myeloid Leukemia
- Studies Excluded From the Analysis of Chronic Myeloid Leukemia
- Risk/Protective Factors
- Risk/Protective Factors for Chronic Myeloid Leukemia
- Bibliography
- Abbreviations
- Glossary
- Literature Review
- Introduction
Pramilesh Tekchand Suryawanshi, M.P.H., is an associate epidemiologist at Clarivate. His focus is on hematological malignancies and solid tumors. Previously, Mr. Suryawanshi worked with Pathfinder International in Lepra, the Netherlands Leprosy Relief Foundation, and the National Health Mission. He received his M.P.H. from the Tata Institute of Social Sciences in Mumbai, where he worked on several public health projects, including an assessment of social health insurance schemes. He holds a bachelor’s degree in the Indian system of medicine (Ayurveda) from Rajiv Gandhi University of Health Sciences in Karnataka.
Narendra Parihar, B.D.S., M.P.H., Senior Manager, Epidemiology. Dr Parihar is a team lead at Clarivate Epidemiology. He specializes in modelling and forecasting epidemiology patient populations across multiple indications. His primary areas of interest are cancer epidemiology, rare disease epidemiology, and targeted therapies in cancer. His qualifications include a master’s degree in public health with specialization in health policy, economics, and finance from Tata Institute of Social Sciences Mumbai, and a bachelor’s degree in dental surgery from the Rajasthan University of Health Sciences.